infected animals was confirmed with a clinical dosage of regdanvimab (CT-P59)1
Incheon, South Korea–(Antara/Business Wire.
Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment
